Novartis initiates ascending dose study of PIT565 for rheumatoid arthritis
Novartis is conducting a study to evaluate the safety, tolerability, and pharmacokinetics of PIT565 in rheumatoid arthritis patients.
Asset / Drug
Drug and asset intelligence for PIT565 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.